BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
50.38
+1.29 (2.63%)
At close: Aug 13, 2025, 4:00 PM
50.46
+0.08 (0.16%)
After-hours: Aug 13, 2025, 7:52 PM EDT
BridgeBio Pharma Stock Forecast
Stock Price Forecast
According to 16 professional analysts, the 12-month price target for BridgeBio Pharma stock ranges from a low of $46 to a high of $95. The average analyst price target of $61.69 forecasts a 22.45% increase in the stock price over the next year.
Price Target: $61.69 (+22.45%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BridgeBio Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 7 | 7 |
| Buy | 6 | 6 | 6 | 8 | 9 | 9 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 14 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Maintains $55 → $57 | Buy | Maintains | $55 → $57 | +13.14% | Aug 6, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $60 → $61 | Buy | Maintains | $60 → $61 | +21.08% | Aug 6, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $95 | Buy | Reiterates | $95 | +88.57% | Jul 29, 2025 |
| Truist Securities | Truist Securities | Strong Buy Initiates $66 | Strong Buy | Initiates | $66 | +31.00% | Jul 21, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $63 → $68 | Buy | Maintains | $63 → $68 | +34.97% | Jul 14, 2025 |
Financial Forecast
Revenue This Year
457.84M
from 221.90M
Increased by 106.33%
Revenue Next Year
706.45M
from 457.84M
Increased by 54.30%
EPS This Year
-3.22
from -2.88
EPS Next Year
-2.10
from -3.22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 792.8M | 942.4M | 1.8B |
| Avg | 457.8M | 706.5M | 1.3B |
| Low | 300.4M | 415.8M | 569.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 257.3% | 105.8% | 149.6% |
| Avg | 106.3% | 54.3% | 77.6% |
| Low | 35.4% | -9.2% | -19.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.46 | -1.53 | 1.85 | ||
| Avg | -3.22 | -2.10 | -0.01 | ||
| Low | -3.85 | -3.25 | -1.96 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.